Repligen (NASDAQ:RGEN) Releases FY 2025 Earnings Guidance

Repligen (NASDAQ:RGEN - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.630-1.720 for the period, compared to the consensus earnings per share estimate of 1.710. The company issued revenue guidance of $695.0 million-$720.0 million, compared to the consensus revenue estimate of $700.8 million.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group dropped their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. Royal Bank of Canada reduced their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price on the stock. Finally, StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Monday. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

Repligen Stock Up 3.1 %

NASDAQ:RGEN traded up $4.31 during trading hours on Friday, hitting $141.51. The company's stock had a trading volume of 581,931 shares, compared to its average volume of 717,070. The stock has a market capitalization of $7.95 billion, a P/E ratio of -277.47, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a fifty day moving average of $138.22 and a 200-day moving average of $145.83. Repligen has a 52-week low of $102.97 and a 52-week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the company earned $0.28 EPS. On average, equities analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Insider Activity

In related news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.